(S)-SLV 319 NEW
| Price | Get Latest Price | ||
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2025-12-22 |
Product Details
| Product Name: (S)-SLV 319 | CAS No.: 464213-10-3 |
| Supply Ability: 10g | Release date: 2025/12/22 |
Product Introduction
Bioactivity
| Name | (S)-SLV 319 |
| Description | Ibipinabant (SLV319) is a potent, selective, and orally active cannabinoid CB1 receptor antagonist, with a K_i of 7.8 nM and over 1000-fold selectivity for CB1 compared to CB2 (K_i = 7943 nM). It is utilized in obesity and diabetes research [1] [2] [3]. |
| In vitro | SLV319 competitively inhibits CP-55940 (CB agonist) binding to the human CB1 receptor in CHO cells genetically modified to express this receptor, exhibiting an inhibition constant (K i) of 7.8 nM [1]. Furthermore, SLV319 dose-dependently antagonizes the WIN-55212 (CB1 agonist)-induced release of arachidonic acid in these cells, demonstrating a potency (pA2) of 9.9 [1]. |
| In vivo | SLV319, administered orally at a dosage of 3 mg/kg/day for 28 days, effectively reduces food intake, body weight, and hormonal/metabolic abnormalities in diet-induced obesity (DIO) mice, as well as reverses high-fat diet (HFD)-induced increases in adipose tissue leptin mRNA. At doses ranging from 3-10 mg/kg given daily via oral gavage for 56 days, SLV319 also demonstrates weight loss-independent antidiabetic effects and mitigates β-cell loss in a rat model of progressive β-cell dysfunction. Furthermore, SLV319 counters CB agonist (CP55940)-induced hypotension in rats and hypothermia in mice, showcasing ED 50 values of 5.5 and 3 mg/kg, respectively. In an animal model involving six-week-old male C57Bl/6J mice fed a diet of 60% calories from fat, resulting in body weights exceeding 42 g within 12-14 weeks, a similar dosage and administration method led to significant reductions in food intake, body weight, and adiposity in DIO mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | SLV-319 | SLV 319 | (S) SLV 319 | (S)SLV 319 | SLV319 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $4530.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP2Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2026-07-07 | ||
| $10.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-07 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY